USPTO serial 79345867
RECOMBUMIN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 23, 2024
- Examiner
- PERKINS, ELLEN J
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with RECOMBUMIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Karen Lim
Karen Lim Fross Zelnick Lehrman & Zissu, P.C.151 West 42nd St., 17th FLNew York, NY 10036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry, science and for use in the manufacture of pharmaceuticals; chemical reagents other than for medical or veterinary purposes; diagnostic reagents and preparations, other than for medical or veterinary purposes; chemical excipients for use in the manufacture of pharmaceutical preparations; proteins for industrial purposes; recombinant human albumin for use as a stabilizer and excipient for industrial purposes and for use in the manufacture of cell culture media, cell and tissue storage and preservation media and for the manufacture of diagnostic imaging agents; cell culture reagents for scientific and research use, and chemical preservation reagents for scientific and research use; albumin for use in the manufacture of pharmaceutical products, vaccines, cellular therapies, regenerative medicines and gene therapies; protein in raw material form for scientific and medical research | ACTIVE | — |
| 005 | Pharmaceuticals for the treatment or prophylaxis of viral, bacterial, fungal, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, respiratory, digestive, neurological, neurodegenerative, neuromuscular, central nervous system, gastrointestinal, hormonal, dermatological, psychiatric, immune system, urinary, angiogenic, genetic, menopausal, and pain related diseases and disorders; pharmaceutical products and substances for the treatment or prophylaxis of viral, bacterial, fungal, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, respiratory, digestive, neurological, neurodegenerative, neuromuscular, central nervous system, gastrointestinal, hormonal, dermatological, psychiatric, immune system, urinary, angiogenic, genetic, menopausal, and pain related diseases and disorders; albumin, chemical preparations, synthetic peptides, protein supplements, monoclonal, polyclonal, immunological, native and recombinant antibodies for medical and veterinary use, cells for medical and veterinary use, viruses, live viruses, live- attenuated viruses, attenuated viruses, and virus-like particles and viral vectors for medical and veterinary use, vaccines, growth factors for medical and veterinary use, immune modulators for medical and veterinary use, monoclonal antibodies, biological tissue and tissue cultures, recombinant proteins for medical and veterinary use, nucleic acid sequences, blood plasma, blood components for medical and veterinary use, all being for pharmaceutical use for the treatment or prophylaxis of viral, bacterial, fungal, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, hematological, ophthalmic, respiratory, digestive, neurological, neurodegenerative, neuromuscular, central nervous system, gastrointestinal, hormonal, dermatological, psychiatric, immune system, urinary, angiogenic, genetic, menopausal, and pain related diseases and disorders; reagents for medical use; diagnostic reagents for medical use; protein supplements for pharmaceutical purposes; albuminous preparations for medical or veterinary purposes; recombinant albumin for biological therapeutic purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Sartorius Albumedix Limited
- Other trademarks owned by Albumedix Ltd
- Other trademarks owned by Albumedix Ltd
- Other trademarks owned by Albumedix Ltd
- Other trademarks in Class 001
- Other trademarks in Class 005
- Similar marks named RECOMBUMIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 16, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 16, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 16, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 16, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 16, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 11, 2025 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Nov 9, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 23, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 23, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 24, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 23, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 23, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 6, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 6, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 5, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 17, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 17, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 17, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 13, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 31, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 27, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 27, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 3, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 3, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 3, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 23, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 3, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 3, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 2, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 16, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 15, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 7, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 29, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 2, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 29, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 27, 2022 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jul 21, 2022 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |